Pathology Labs Replace Microscopes with Digital Imaging
|
By LabMedica International staff writers Posted on 29 Dec 2011 |
Microscopes are being replaced with digital imaging in pathology laboratories in the southern part of Sweden.
Traditional microscope glass slides are turned into digital images, which are then analyzed by pathologists directly from the computer screen, instead of using regular microscopes.
The revolution, which has already occurred in radiology, is now taking place in pathology. The contracted delivery not only digitizes the slides but also will completely renew IT support for all workflows of the pathology laboratories in the Skåne region.
Labvantage (Somerset, NJ, USA) will deliver a USD 4 million turnkey solution for digitizing the histopathological workflows in the whole region. The system will be possibly the largest such installation in the world and among the first of its kind in northern Europe. The digital slides will reside in Hitachi’s (Tokyo, Japan) Content Platform, which employs distributed object storage. All of the images will be kept well protected and duplicated across several physical discs. This makes the traditional backing up of data unnecessary.
Currently the four pathology laboratories run by Region Skåne produce about 400,000 histological microscope slides a year. The samples are prepared into microscope slides and are then physically distributed to pathologists. Slides are then analyzed using regular microscopes. There is currently limited IT support for the workflow, making it difficult to track the status of pending cases and to identify the bottlenecks in the production workflow.
The difficulties in this method are mostly related to physical slides, which can only reside–and be analyzed–in one place at a time. With the digital pathology in place, all pathologists from all laboratories of Skåne can gain access to all cases and related slides. Together with the introduction of digital pathology, another goal of Region Skåne is to introduce so-called LEAN workflows.
The digitizing will not only ease the distribution of slides for the pathologists’ viewing but will also solve the needs for storage. Swedish law requires Region Skåne to keep all slides for a minimum of 20 years, and today this requires a lot of physical space. It is also difficult to retrieve a particular case from the archive. In the digitized format, the annual production of about 400,000 glass slides will consume 300 terabytes of storage each year.
The unique changeover both in its scope and in scale is to be supplied by Software Point. A key component in the delivery is a new workflow management system, which will manage both the preanalytical and analytical stages of the laboratory process. An adapted version of Software Point’s (Espoo, Finland) C5 LIMS will be in total charge of managing the workflows and tracking all events within. It will maintain a real-time status of each sample, slide, and case, and will ease the work of both laboratory technicians and pathologists with advanced functionalities such as integration to laboratory automation, datamatrix labeling of all objects, and speech recognition for pathologists.
"This is an important milestone for us. Our workflow-centric C5 LIMS, complemented with the best of breed systems from Aperio (Vista, CA, USA) and Hitachi, make up a solution unlike anything else on the market. We see tremendous potential in digital pathology and this is one key element in our strategy for further expanding the position of our LIMS in the healthcare marketplace," comments Andrea Holmberg, CEO of Software Point.
Related Links:
Labvantage
Software Point
Aperio
Traditional microscope glass slides are turned into digital images, which are then analyzed by pathologists directly from the computer screen, instead of using regular microscopes.
The revolution, which has already occurred in radiology, is now taking place in pathology. The contracted delivery not only digitizes the slides but also will completely renew IT support for all workflows of the pathology laboratories in the Skåne region.
Labvantage (Somerset, NJ, USA) will deliver a USD 4 million turnkey solution for digitizing the histopathological workflows in the whole region. The system will be possibly the largest such installation in the world and among the first of its kind in northern Europe. The digital slides will reside in Hitachi’s (Tokyo, Japan) Content Platform, which employs distributed object storage. All of the images will be kept well protected and duplicated across several physical discs. This makes the traditional backing up of data unnecessary.
Currently the four pathology laboratories run by Region Skåne produce about 400,000 histological microscope slides a year. The samples are prepared into microscope slides and are then physically distributed to pathologists. Slides are then analyzed using regular microscopes. There is currently limited IT support for the workflow, making it difficult to track the status of pending cases and to identify the bottlenecks in the production workflow.
The difficulties in this method are mostly related to physical slides, which can only reside–and be analyzed–in one place at a time. With the digital pathology in place, all pathologists from all laboratories of Skåne can gain access to all cases and related slides. Together with the introduction of digital pathology, another goal of Region Skåne is to introduce so-called LEAN workflows.
The digitizing will not only ease the distribution of slides for the pathologists’ viewing but will also solve the needs for storage. Swedish law requires Region Skåne to keep all slides for a minimum of 20 years, and today this requires a lot of physical space. It is also difficult to retrieve a particular case from the archive. In the digitized format, the annual production of about 400,000 glass slides will consume 300 terabytes of storage each year.
The unique changeover both in its scope and in scale is to be supplied by Software Point. A key component in the delivery is a new workflow management system, which will manage both the preanalytical and analytical stages of the laboratory process. An adapted version of Software Point’s (Espoo, Finland) C5 LIMS will be in total charge of managing the workflows and tracking all events within. It will maintain a real-time status of each sample, slide, and case, and will ease the work of both laboratory technicians and pathologists with advanced functionalities such as integration to laboratory automation, datamatrix labeling of all objects, and speech recognition for pathologists.
"This is an important milestone for us. Our workflow-centric C5 LIMS, complemented with the best of breed systems from Aperio (Vista, CA, USA) and Hitachi, make up a solution unlike anything else on the market. We see tremendous potential in digital pathology and this is one key element in our strategy for further expanding the position of our LIMS in the healthcare marketplace," comments Andrea Holmberg, CEO of Software Point.
Related Links:
Labvantage
Software Point
Aperio
Latest Pathology News
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Channels
Clinical Chemistry
view channel
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read more
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read moreMolecular Diagnostics
view channel
Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








